Fibrocytes regulate liver fibrosis
纤维细胞调节肝纤维化
基本信息
- 批准号:9218867
- 负责人:
- 金额:$ 34.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-02-01 至 2021-01-31
- 项目状态:已结题
- 来源:
- 关键词:5&apos Untranslated RegionsAblationAlpha CellAmyloidAnti-Inflammatory AgentsAnti-inflammatoryArchivesAttenuatedBiologyBone MarrowCellsChronicCirrhosisClinical TrialsCollagenCollagen Type IDDR1 geneDataDepositionDevelopmentDietDiphtheria ToxinEnhancersEtiologyExtracellular Matrix ProteinsFibroblast Growth FactorFibrosisGeneticGoalsHealthcareHematopoieticHepaticITGAM geneInflammationInflammatoryInjuryInjury to LiverIntegrinsInterleukin-1KidneyLabelLigandsLiver FibrosisLungMDR3 deficiencyMediatingModelingMusMutationMyeloid CellsMyofibroblastPTPRC genePathogenesisPatientsPharmacologyPhospholipidsPlayPopulationProductionProteinsRANTESRecruitment ActivityRegulationReportingResistanceRoleSerumSideSignal TransductionSkinSourceStimulusTNF geneTamoxifenTestingTherapeuticTherapeutic EffectTransgenic OrganismsTranslationsTransplantationType I ProcollagenUrokinasebasecare burdencollagenasecytokinefast foodfibrogenesisimmunoregulationinhibitor/antagonistinjuredintrahepaticliver developmentliver injurymacrophagemajor urinary proteinsmigrationmutantnonalcoholic steatohepatitisoverexpressionparacrinepre-clinicalpreventpromoterresponsetherapeutic evaluationtranscriptome sequencingtreatment choice
项目摘要
ABSTRACT:
Bone marrow-derived fibrocytes, designated as CD45+ and Collagen Type I+ cells, were implicated in the
pathogenesis of lung, skin, and kidney fibrosis due to their ability to differentiate into fibrogenic myofibroblasts.
We have demonstrated that fibrocytes contribute to 4-6% of Col1a1-producing cells in the fibrotic liver1,2,
suggesting that fibrocytes are not a significant source of ECM. Puzzled by these data, we continued
investigating fibrocytes, and have now obtained strong preliminary data suggesting that genetic or
pharmacological inhibition of fibrocytes attenuates development of liver fibrosis by 50%. The goal of
this proposal is to determine the role of fibrocytes in the pathogenesis of liver fibrosis and develop therapeutic
strategies of their inhibition. We hypothesize that targeting fibrocytes will inhibit liver fibrosis. The central
hypothesis is that fibrocytes give rise to unique populations of fibrogenic myofibroblasts and pro-inflammatory
myeloid cells that synergistically facilitate liver fibrosis by secreting TGF-1, TNF-, IL-11, CCL5 and other
regulatory cytokines promoting M1 (and inhibiting anti-inflammatory M2) macrophages. To test this hypothesis,
four complimentary AIMs have been developed: AIM 1. The role of fibrocytes in liver fibrosis will be determined
in fibrocyte-ablated mice (versus wt mice) subjected to chronic toxic, cholestatic, and NASH liver injury.
Genetic ablation of fibrocytes will be achieved by overexpression of Diphtheria toxin- (DTA) specifically in
fibrocytes, and has not been previously reported. We anticipate that liver fibrosis of different etiologies is
strongly attenuated in fibrocyte-ablated mice. AIM 2. We have developed a cell fate mapping approach to
determine fibrocyte function(s), and the mechanism by which fibrocytes mediate liver fibrosis. Using a side-by-
side comparison of wt and fibrocyte-ablated mice, we will determine if fibrocytes promote intrahepatic cytokine
secretion, and regulate activation of M1 (vs M2) macrophages. We predict that fibrocytes play a major
immunoregulatory role in liver fibrosis. AIM 3. The role of Col1a1 in regulation of fibrocyte biology will be
studied by comparing wt and Col1a15'SL-mutant fibrocytes (with the “loss” of Col1a1 function) and Col11rr-
mutant fibrocytes (with “gain” of Col1a1 function). The mechanism of Col1a1 signaling in fibrocytes, leading to
their proliferation/activation, will be examined in primary and immortalized fibrocytes. We anticipate that Col1a1
regulates vital functions of fibrocytes via interaction with its ligand(s), such as DDR1 and 21 integrins. AIM 4.
We test if therapeutic administration of Serum Amyloid P (SAP), a natural inhibitor of fibrocytes, can effectively
attenuate liver fibrosis of different etiologies in mice, e.g. via inhibition of fibrocyte proliferation, cytokine
production, and differentiation into myofibroblasts. We will analyze archived patient material to determine
therapeutic potential of SAP for patients with NASH (the relationship between serum SAP, hepatic fibrocytes,
and stage/progression of liver fibrosis). SAP might become a treatment of choice in patients with NASH.
摘要:
骨髓来源的纤维细胞,命名为CD 45+和I型胶原+细胞,参与了细胞凋亡。
由于它们分化成纤维化肌成纤维细胞的能力,肺、皮肤和肾纤维化的发病机制。
我们已经证明,在纤维化肝脏中,纤维细胞占Col 1a 1产生细胞的4-6% 1,2,
表明纤维细胞不是ECM的重要来源。这些数据让我们感到困惑,
研究纤维细胞,现在已经获得了强有力的初步数据,表明遗传或
纤维细胞的药理学抑制使肝纤维化的发展减弱约50%。的目标
该建议旨在确定纤维细胞在肝纤维化发病机制中的作用,
他们的抑制策略。我们假设靶向纤维细胞将抑制肝纤维化。中央
假设是纤维细胞产生独特的纤维化肌成纤维细胞群和促炎性细胞群,
骨髓细胞通过分泌TGF-β 1、TNF-α、IL-1 β 1、CCL 5和其他因子协同促进肝纤维化
促进M1(和抑制抗炎M2)巨噬细胞的调节细胞因子。为了检验这一假设,
已经开发了四种互补的AIM:AIM 1。纤维细胞在肝纤维化中的作用将被确定
在经受慢性毒性、胆汁淤积性和NASH肝损伤的纤维细胞消融小鼠(相对于野生型小鼠)中。
纤维细胞的基因消融将通过白喉毒素-β(DTA)的特异性过表达来实现,
纤维细胞,以前没有报道过。我们预期不同病因的肝纤维化是
在纤维细胞消融的小鼠中强烈减弱。AIM 2.我们已经开发了一种细胞命运映射方法,
确定纤维细胞功能和纤维细胞介导肝纤维化的机制。使用一个并排的-
通过比较WT和纤维细胞消融小鼠,我们将确定纤维细胞是否促进肝内细胞因子
分泌,并调节M1(vs M2)巨噬细胞的活化。我们预测,纤维细胞发挥主要作用,
免疫调节在肝纤维化中作用。AIM 3. Col 1a 1在纤维细胞生物学调节中的作用将是
通过比较野生型和Col 1a 15 'SL突变型纤维细胞(具有Col 1a 1功能的“丧失”)和Col 1a 11 rr,
突变型纤维细胞(Col 1a 1功能“获得”)。纤维细胞中Col 1a 1信号传导的机制,导致
它们的增殖/活化将在原代和永生化纤维细胞中进行检测。我们预计Col 1a 1
通过与其配体(如DDR 1和DDR2 β 1整联蛋白)的相互作用调节纤维细胞的重要功能。AIM 4.
我们测试了血清淀粉样蛋白P(SAP)(一种天然的纤维细胞抑制剂)的治疗性给药是否能有效地
减轻小鼠中不同病因的肝纤维化,例如通过抑制纤维细胞增殖、细胞因子
产生和分化成肌成纤维细胞。我们将分析存档的患者资料,
SAP对NASH患者的治疗潜力(血清SAP,肝纤维细胞,
和肝纤维化的阶段/进展)。SAP可能成为NASH患者的治疗选择。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Tatiana Kisseleva其他文献
Tatiana Kisseleva的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Tatiana Kisseleva', 18)}}的其他基金
The role of IL-17 signaling in alcohol-induced HCC
IL-17 信号在酒精诱导的 HCC 中的作用
- 批准号:
10463697 - 财政年份:2021
- 资助金额:
$ 34.88万 - 项目类别:
The role of IL-17 signaling in alcohol-induced HCC
IL-17 信号在酒精诱导的 HCC 中的作用
- 批准号:
10299157 - 财政年份:2021
- 资助金额:
$ 34.88万 - 项目类别:
Novel IL-23 inhibitor for the treatment of alcohol associated liver disease
用于治疗酒精相关性肝病的新型 IL-23 抑制剂
- 批准号:
10482350 - 财政年份:2020
- 资助金额:
$ 34.88万 - 项目类别:
Novel IL-23 inhibitor for the treatment of alcohol associated liver disease
用于治疗酒精相关性肝病的新型 IL-23 抑制剂
- 批准号:
10266186 - 财政年份:2020
- 资助金额:
$ 34.88万 - 项目类别:
The Role of Portal Fibroblasts in Cholestatic Liver Fibrosis
门静脉成纤维细胞在胆汁淤积性肝纤维化中的作用
- 批准号:
10441586 - 财政年份:2014
- 资助金额:
$ 34.88万 - 项目类别:
Inactivation of Hepatic Stellate Cells During Reversal of Liver Fibrosis
肝纤维化逆转过程中肝星状细胞失活
- 批准号:
8694267 - 财政年份:2014
- 资助金额:
$ 34.88万 - 项目类别:
The Role of Portal Fibroblasts in Cholestatic Liver Fibrosis
门静脉成纤维细胞在胆汁淤积性肝纤维化中的作用
- 批准号:
10312314 - 财政年份:2014
- 资助金额:
$ 34.88万 - 项目类别:
Epigenetics of human Hepatic Stellate Cells (HSCs) in NASH
NASH 中人肝星状细胞 (HSC) 的表观遗传学
- 批准号:
10367096 - 财政年份:2014
- 资助金额:
$ 34.88万 - 项目类别:
Inactivation of Hepatic Stellate Cells During Reversal of Liver Fibrosis
肝纤维化逆转过程中肝星状细胞失活
- 批准号:
9271180 - 财政年份:2014
- 资助金额:
$ 34.88万 - 项目类别:
相似海外基金
Impact of alternative polyadenylation of 3'-untranslated regions in the PI3K/AKT cascade on microRNA
PI3K/AKT 级联中 3-非翻译区的替代多聚腺苷酸化对 microRNA 的影响
- 批准号:
573541-2022 - 财政年份:2022
- 资助金额:
$ 34.88万 - 项目类别:
University Undergraduate Student Research Awards
How do untranslated regions of cannabinoid receptor type 1 mRNA determine receptor subcellular localisation and function?
1 型大麻素受体 mRNA 的非翻译区如何决定受体亚细胞定位和功能?
- 批准号:
2744317 - 财政年份:2022
- 资助金额:
$ 34.88万 - 项目类别:
Studentship
MICA:Synthetic untranslated regions for direct delivery of therapeutic mRNAs
MICA:用于直接递送治疗性 mRNA 的合成非翻译区
- 批准号:
MR/V010948/1 - 财政年份:2021
- 资助金额:
$ 34.88万 - 项目类别:
Research Grant
Translational Control by 5'-untranslated regions
5-非翻译区域的翻译控制
- 批准号:
10019570 - 财政年份:2019
- 资助金额:
$ 34.88万 - 项目类别:
Translational Control by 5'-untranslated regions
5-非翻译区域的翻译控制
- 批准号:
10223370 - 财政年份:2019
- 资助金额:
$ 34.88万 - 项目类别:
Translational Control by 5'-untranslated regions
5-非翻译区域的翻译控制
- 批准号:
10455108 - 财政年份:2019
- 资助金额:
$ 34.88万 - 项目类别:
Synergistic microRNA-binding sites, and 3' untranslated regions: a dialogue of silence
协同的 microRNA 结合位点和 3 非翻译区:沉默的对话
- 批准号:
255762 - 财政年份:2012
- 资助金额:
$ 34.88万 - 项目类别:
Operating Grants
Analysis of long untranslated regions in Nipah virus genome
尼帕病毒基因组长非翻译区分析
- 批准号:
20790351 - 财政年份:2008
- 资助金额:
$ 34.88万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Search for mRNA elements involved in the compatibility between 5' untranslated regions and coding regions in chloroplast translation
寻找参与叶绿体翻译中 5 非翻译区和编码区之间兼容性的 mRNA 元件
- 批准号:
19370021 - 财政年份:2007
- 资助金额:
$ 34.88万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Post-transcriptional Regulation of PPAR-g Expression by 5'-Untranslated Regions
5-非翻译区对 PPAR-g 表达的转录后调控
- 批准号:
7131841 - 财政年份:2006
- 资助金额:
$ 34.88万 - 项目类别: